Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.894 SEK | +1.13% |
|
-4.49% | -27.32% |
06-11 | Nanexa AB Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes | CI |
05-15 | Nanexa AB Elects Hanna Tilus as Members of the Board | CI |
Turnover - Change in analysts' estimates
EBIT - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
EBIT
Cash or Net Debt
- Stock Market
- Equities
- NANEXA Stock
- Revisions Nanexa AB